Corrine K Welt1, Enrico Carmina. 1. Reproductive Endocrine, BHX 511, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114. cwelt@partners.org.
Abstract
CONTEXT: Polycystic ovary syndrome (PCOS) is diagnosed during the reproductive years when women present with 2 of 3 of the following criteria: 1) irregular menstrual cycles or anovulation, 2) hyperandrogenism, and 3) PCO morphology. However, there is evidence that PCOS can be identified from early infancy to puberty based on predisposing environmental influences. There is also increasing information about the PCOS phenotype after menopause. The goal of this review is to summarize current knowledge about the appearance of PCOS at different life stages and the influence of reproductive maturation and senescence on the PCOS phenotype. EVIDENCE: PubMed, the bibliography from the Evidence-Based PCOS Workshop, and the reference lists from identified manuscripts were reviewed. EVIDENCE SYNTHESIS: The current data suggest that daughters of women with PCOS have a greater follicle complement and mild metabolic abnormalities from infancy. PCOS is often diagnosed in puberty with the onset of hyperandrogenism and may be preceded by premature pubarche. During the reproductive years, there is a gradual decrease in the severity of the cardinal features of PCOS. Menopausal data suggest that the majority of women who had PCOS during their reproductive years continue to manifest cardiovascular risk factors. However, the majority do not present an increased risk for cardiovascular morbidity and mortality, perhaps because women with no history of PCOS may catch up after menopause. CONCLUSION: The current data provide a comprehensive starting point to understand the phenotype of PCOS across the lifespan. However, limitations such as a bias of ascertainment in childhood, age-based changes during reproductive life, and the small numbers studied during menopause point to the need for additional longitudinal studies to expand the current knowledge.
CONTEXT: Polycystic ovary syndrome (PCOS) is diagnosed during the reproductive years when women present with 2 of 3 of the following criteria: 1) irregular menstrual cycles or anovulation, 2) hyperandrogenism, and 3) PCO morphology. However, there is evidence that PCOS can be identified from early infancy to puberty based on predisposing environmental influences. There is also increasing information about the PCOS phenotype after menopause. The goal of this review is to summarize current knowledge about the appearance of PCOS at different life stages and the influence of reproductive maturation and senescence on the PCOS phenotype. EVIDENCE: PubMed, the bibliography from the Evidence-Based PCOS Workshop, and the reference lists from identified manuscripts were reviewed. EVIDENCE SYNTHESIS: The current data suggest that daughters of women with PCOS have a greater follicle complement and mild metabolic abnormalities from infancy. PCOS is often diagnosed in puberty with the onset of hyperandrogenism and may be preceded by premature pubarche. During the reproductive years, there is a gradual decrease in the severity of the cardinal features of PCOS. Menopausal data suggest that the majority of women who had PCOS during their reproductive years continue to manifest cardiovascular risk factors. However, the majority do not present an increased risk for cardiovascular morbidity and mortality, perhaps because women with no history of PCOS may catch up after menopause. CONCLUSION: The current data provide a comprehensive starting point to understand the phenotype of PCOS across the lifespan. However, limitations such as a bias of ascertainment in childhood, age-based changes during reproductive life, and the small numbers studied during menopause point to the need for additional longitudinal studies to expand the current knowledge.
Authors: Christopher R McCartney; Susan K Blank; Kathleen A Prendergast; Sandhya Chhabra; Christine A Eagleson; Kristin D Helm; Richard Yoo; R Jeffrey Chang; Carol M Foster; Sonia Caprio; John C Marshall Journal: J Clin Endocrinol Metab Date: 2006-11-21 Impact factor: 5.958
Authors: E Dahlgren; S Johansson; G Lindstedt; F Knutsson; A Odén; P O Janson; L A Mattson; N Crona; P A Lundberg Journal: Fertil Steril Date: 1992-03 Impact factor: 7.329
Authors: Hyun-Jun Kim; Judith M Adams; Jens A Gudmundsson; Gudmundur Arason; Cindy T Pau; Corrine K Welt Journal: Fertil Steril Date: 2017-08-12 Impact factor: 7.329
Authors: Maryam Kazemi; Brittany Y Jarrett; Stephen A Parry; Anna E Thalacker-Mercer; Kathleen M Hoeger; Steven D Spandorfer; Marla E Lujan Journal: J Clin Endocrinol Metab Date: 2020-09-01 Impact factor: 5.958
Authors: Alex J Polotsky; Amanda A Allshouse; Sybil L Crawford; Sioban D Harlow; Naila Khalil; Rasa Kazlauskaite; Nanette Santoro; Richard S Legro Journal: J Clin Endocrinol Metab Date: 2014-02-11 Impact factor: 5.958
Authors: Triin Laisk-Podar; Cecilia M Lindgren; Maire Peters; Juha S Tapanainen; Cornelis B Lambalk; Andres Salumets; Reedik Mägi Journal: Trends Endocrinol Metab Date: 2016-05-21 Impact factor: 12.015